AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02977845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong
Description: Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients.
Study NCT00254683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT with FDG
Description: PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
Study NCT02279836 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SC20 Colonoscope
Description: Single Arm Post-Marketing Study of SC20 Colonoscope
Study NCT03442517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Lifestyle Intervention
Description: Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.
Study NCT03442517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual prenatal care
Description: Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
Study NCT02152514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine/Sufentanil
Study NCT03915509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis
Description: Lasak Impladent Implants (sandblasted)
Study NCT03915509 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis
Description: Lasak Impladent Implants (sandblasted)
Study NCT00651326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Study NCT02152514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Study NCT02152514 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PCA
Study NCT01119365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Light is administered through a custom designed mask with LED lights.
Study NCT02114385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: 9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
Study NCT02114385 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL
Description: Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
Study NCT04593576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity protocol/out door sports
Description: Warm up exercise will be administered for 10 minutes, then one-to-five small group of instruction based activity will be administered for 15 minutes. After this whole group will be engaged in ball exercise and cooperative ball games for 20 minutes. At the end cool down and reward activity will be done with participants for 15v minutes.~Total 1 hour physical activity protocol will be administered twice a week.
Study NCT04593576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive table teaching speech therapy
Description: Control group participants will be given speech therapy session based on intensive table teaching for 30 minutes twice a week.
Study NCT00549679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256066
Description: PDE4 inhibitor
Study NCT00549679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02694328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 3831
Description: Daily dosing
Study NCT02694328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Daily dosing
Study NCT04060446 — intervention group
Intervention type: DEVICE
Intervention: Medical Device
Description: Smoke cigarettes with CReSSMicro topography measurement device and BioRadio device
Study NCT04060446 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04060446 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tobacco Smoking
Description: Smoke cigarettes
Study NCT04400786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent treatment
Description: According to the feeling of pain, the on-demand treatment group is prescribed with or without Imrecoxib (100mg/tablet, 100mg.prn.po), but the maximal dose does not exceed 100 mg per time, twice (morning and evening) per day. The duration lasted for 24 weeks.
Study NCT04400786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous treatment
Description: The continuous treatment group is prescribed Imrecoxib (100mg.bid.po) regardless of the pain in the treatment course for 24 weeks.
Study NCT03953573 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey completed at 1 day, 8 days 1 or 3 months post delivery
Study NCT03394287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT03394287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study NCT02627430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 Inhibitor AT13387
Description: Given IV
Study NCT02627430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02627430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02627430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study NCT04495842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Oil Blend
Description: 5 drops of on a tester strip
Study NCT04495842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Blend
Description: 5 drops on a tester strip
Study NCT01382446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: 0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
Study NCT01382446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste
Description: Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
Study NCT03930043 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomic shotgun sequencing
Description: preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen
Study NCT00927615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab
Description: 0.25 mg/kg body weight (intracoronary)
Study NCT00927615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abciximab
Description: 0.25 mg/kg body weight (intravenous)
Study NCT04890327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based family health history tool
Description: Web-based tool that collects subject's family health history through a series of questions and generates a pedigree which documents a risk assessment report for the physician to use. The risk assessment report uses standard, validated risk scores including GAIL , CLAUS, BRCAPRO which measure breast cancer risk, and MMRPRO which measures endometrial cancer risk, MELAPRO which measures melanoma cancer risk, and PANCPRO which measures pancreatic cancer risk
Study NCT01960023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
Study NCT02662114 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
Study NCT01960023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study.
Study NCT01711463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: 50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
Study NCT01711463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaled once daily for 7 days in each treatment period.
Study NCT03413579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab ( h-R3)
Description: Humanized monoclonal antibody
Study NCT03413579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01216644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², d1, i.v., every 2 weeks
Study NCT01216644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², d1, i.v., every 2 weeks
Study NCT01216644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2, d1, i.v., every 2 weeks
Study NCT00567918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: Ophthalmic suspension
Study NCT02608749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated care (IC)
Description: Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
Study NCT02608749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower extremity exercise (LEE)
Description: Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
Study NCT01216644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 50 mg/m2, d1, i.v., every 3 weeks
Study NCT01216644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 60 mg/m², d1, i.v., every 3 weeks
Study NCT01216644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 200 mg/m², d1-d21, i.v., every 3 weeks
Study NCT02036983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block (TAP BLOCK)
Description: Ultrasound guided TAP block with local anesthetics and dexamethasone.
Study NCT02036983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Instillation of surgical site with local anesthetic.
Description: Instillation of surgical site with local anesthetics and dexamethasone.
Study NCT02036983 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Opioid IV medications (Control)
Description: Standard anesthetic technique.
Study NCT02411968 — intervention group
Intervention type: OTHER
Intervention: 111In-Girentuximab DOTA SPECT
Study NCT00494559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Actos 15mg once a day before breakfast
Study NCT00494559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug with the same appearance as actos
Study NCT02635334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg orally
Study NCT02635334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast 10 mg orally
Study NCT02635334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02635334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04448015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perinatal Opioid Use Disorder Education and Enhanced Perinatal Care
Description: University of Utah clinicians will provide face-to-face, online, and written training materials for health, mental health, and substance use service providers in Carbon and Emery Counties, UT.
Study NCT04014543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gastronomy
Description: to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times.
Study NCT00815191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a forced-air warming cover
Description: A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
Study NCT00815191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vital HEAT (vH2) Temperature Management System
Description: The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
Study NCT03839836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backpack child's body weight
Description: Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
Study NCT03527290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.
Study NCT03527290 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiometabolic Health Diet
Description: The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
Study NCT03192033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arterial closure to ensure hemostasis at femoral artery puncture points
Description: Arterial closure devices used: Proglide® (Abbott)
Study NCT03192033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Proglide® (Abbott)
Description: Arterial closure device used: Proglide® (Abbott)
Study NCT03192033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Femoseal® (Terumo)
Description: Arterial closure device used: Femoseal® (Terumo)
Study NCT03192033 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arterial closure to ensure hemostasis at femoral artery puncture points
Description: Arterial closure device used: Femoseal® (Terumo)
Study NCT02737995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose infusion
Description: Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
Study NCT04609930 — intervention group
Intervention type: DRUG
Intervention: Anti-PD-1 or anti-PD-L1
Description: Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1.
Study NCT04433559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 1,5 mg oral tablets
Description: Use of tadalafil in the treatment of FSIAD
Study NCT04433559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablets
Description: Use of placebo in control group
Study NCT03947528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarpogrelate HCL 300mg
Description: a single oral dose administration in healthy volunteers under fed condition
Study NCT03947528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sarpogrelate HCL 300mg
Description: a single oral dose administration in healthy volunteers under fed condition
Study NCT00215514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
Study NCT00215514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
Study NCT00215514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).